About Lysosomal acid lipase/cholesteryl ester hydrolase
Lysosomal acid lipase/cholesteryl ester hydrolase (LIPA) is a protein
from Homo sapiens identified by UniProt accession
P38571, 399 residues long.
MolForge cross-references it against 0 known binders and
231 disease associations.
Target properties
| Protein name | Lysosomal acid lipase/cholesteryl ester hydrolase |
| UniProt accession | P38571 |
| Gene | LIPA |
| Organism | Homo sapiens |
| Length | 399 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (231)
Diseases linked to this target (Open Targets).
- lysosomal acid lipase deficiency · score 0.80
- Wolman disease · score 0.79
- cholesteryl ester storage disease · score 0.78
- Cholestasis · score 0.46
- cholestasis · score 0.46
- Abnormality of the cardiovascular system · score 0.41
- Hypercholesterolemia · score 0.37
- neuroinflammatory disorder · score 0.37
- hydrops fetalis · score 0.37
- coronary artery disease · score 0.35
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P38571-F1 | alphafold | PREDICTED | 91.54 | — |
Amino-acid sequence (399 residues)
MKMRFLGLVV CLVLWTLHSE GSGGKLTAVD PETNMNVSEI ISYWGFPSEE YLVETEDGYI LCLNRIPHGR KNHSDKGPKP VVFLQHGLLA DSSNWVTNLA NSSLGFILAD AGFDVWMGNS RGNTWSRKHK TLSVSQDEFW AFSYDEMAKY DLPASINFIL NKTGQEQVYY VGHSQGTTIG FIAFSQIPEL AKRIKMFFAL GPVASVAFCT SPMAKLGRLP DHLIKDLFGD KEFLPQSAFL KWLGTHVCTH VILKELCGNL CFLLCGFNER NLNMSRVDVY TTHSPAGTSV QNMLHWSQAV KFQKFQAFDW GSSAKNYFHY NQSYPPTYNV KDMLVPTAVW SGGHDWLADV YDVNILLTQI TNLVFHESIP EWEHLDFIWG LDAPWRLYNK IINLMRKYQ
Explore Lysosomal acid lipase/cholesteryl ester hydrolase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets